CClinicalTrials.gg
CompletedNCT02332070MARCEUpdated Feb 12, 2018

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

An observational study in Acute Kidney Injury and Renal Insufficiency, sponsored by Baylor Research Institute. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2018-02-12.

Sponsored by Baylor Research Institute · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
965
Sex
All
01

Study summary

  1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time

    1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
    2. Thakar Acute Renal Failure (ARF) score (1 to 17)
  2. To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Read the detailed description

Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.

Specific Aims:

  1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time

    1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
    2. Thakar Acute Renal Failure (ARF) score (1 to 17)
  2. To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality

Methods

Study Design: Retrospective cohort

Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).

Excluded Cases

  1. Use of contrast agent other than IOCM with the preoperative angiogram
  2. Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
  3. Operations where there is implantation of mechanical assist devices or cardiac transplant

Measurements:

  1. CI-AKI will be assessed by several methods during the period from angiography to cardiac surgery:

    1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
    2. Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
    3. Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
    4. Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  2. CSA-AKI will be defined by several methods:

    1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
    2. Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
    3. Conventional singular derived from CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
    4. Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
  3. MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
  4. RRT will include at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
  5. All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
  6. All-cause mortality will be reported as inpatient, 30-day, and one-year
  7. Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
  8. Baseline eGFR will be calculated using the CKD-EPI formula

    GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black]

    Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.

  9. Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time, coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI will be reported in baseline characteristics and considered as candidates for multivariable models
02

Conditions studied

  • Acute Kidney Injury
  • Renal Insufficiency

Keywords

  • acute kidney injury
  • coronary angiography
  • cardiac surgery
  • adverse events
  • iodinated contrast
  • Thoracic Surgery
03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's enrollment of 965 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Baylor Research Institute is the lead sponsor of 219 studies on the registry; 49 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 9 (39%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one baseline and postoperative serum creatinine (mg/dl).

Inclusion criteria

  1. Cardiac surgery with or without cardiac valve surgery
  2. At least one baseline and postoperative serum creatinine (mg/dl)

Exclusion criteria

Exclusion Criteria:

  1. Use of contrast agent other than IOCM with the preoperative angiogram
  2. Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
  3. Operations where there is implantation of mechanical assist devices or cardiac transplant
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
965 participants (actual)
Patient registry
No

Interventions

  • Procedurecardiac surgery

    coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass

06

What researchers measure

Primary outcomes

  1. Contrast-induced acute kidney injury

    KDIGO definition

    Time frame: 7 days

  2. Cardiac surgery associated acute kidney injury

    KDIGO definition

    Time frame: 7 days

  3. Major adverse renal and cardiac events

    Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death

    Time frame: 30 days

Secondary outcomes

  1. Renal replacement therapy

    at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification

    Time frame: 30 days

  2. Myocardial Infarction

    Myocardial infarction as defined by STS

    Time frame: 30 days

  3. Stroke

    Stroke as defined by STS

    Time frame: 30 days

  4. Heart failure

    Heart failure

    Time frame: 30 days

  5. Hospitalization for renal reasons

    Hospitalization for renal reasons

    Time frame: 30 days

  6. Hospitalization for cardiac reasons

    Hospitalization for cardiac reaons

    Time frame: 30 days

  7. Death

    Death

    Time frame: 30 days

  8. All-cause hospitalization

    All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database

    Time frame: 30 days

  9. Days out of the hospital and alive

    Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure

    Time frame: 1 year

07

Study locations

1 site
  • Baylor Heart and Vascular Institute
    Dallas, Texas 75226, United States
08

References and documents

Publications

  • McCullough PA, Brown JR. Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. Cardiorenal Med. 2011;1(4):220-234. doi: 10.1159/000332384. Epub 2011 Oct 4. PubMed 22164156 ↗
  • Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56. doi: 10.2215/CJN.02440213. Epub 2013 Dec 5. PubMed 24311708 ↗
  • Tecson KM, Brown D, Choi JW, Feghali G, Gonzalez-Stawinski GV, Hamman BL, Hebeler R, Lander SR, Lima B, Potluri S, Schussler JM, Stoler RC, Velasco C, McCullough PA. Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. Ann Thorac Surg. 2018 Jun;105(6):1724-1730. doi: 10.1016/j.athoracsur.2018.01.010. Epub 2018 Feb 2. PubMed 29408241 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02332070
Lead sponsor
Baylor Research Institute
Collaborators
GE Healthcare
Responsible party
Sponsor
First posted
Jan 6, 2015
Start date
Jan 2015
Primary completion
Feb 2017
Completion
Feb 2018
Last update
Feb 12, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion